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Abstract Aim: We herein describe the establishment of the Helsinki Vascularized Composite 
Allotransplantation (VCA) program and its execution in the ﬁrst two face transplant cases. 
Methods & patients: The Helsinki VCA program initially required the fulﬁllment of legal, hospi- 
tal, ﬁnancial, and ethical requirements. Thereafter, the assembling of a multidisciplinary team 
commenced. A team of Plastic, maxillofacial and ENT surgeons comprise the facial VCA team. 
The protocol involves collaboration with the Solid Organ Transplant (SOT) team, transplant 
immunology, immunosuppression, microbiology, psychiatric evaluation, well-deﬁned VCA indi- 
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cations and informed consent. Between 2011 and 2017 two patients were selected for trans- 
plantation. Both patients had a severe composite facial deformity involving the maxilla and 
mandible following earlier ballistic injury. 
Results: Patient 1 was a 35 year-old male who underwent successful near total face transplan- 
tation in February 2016 and at 30 months he has a good aesthetic outcome with symmetrical 
restoration of the central face and good sensory and symmetrical motor functional outcomes. 
Patient 2 was a 58 year-old male who underwent full face transplantation in March 2018 and at 
5 months he has recovered without major problems. 
Conclusion: A successful facial VCA program requires a well-prepared research protocol, ex- 
perts from multiple specialties and careful patient selection. The establishment of the Helsinki 
VCA program required long and thorough planning and resulted in the ﬁrst two Nordic face 
transplantation cases. This protocol now forms the platform (as a proof of concept) for other 
types of vascularized composite allotransplantations. 
© 2018 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by El- 
sevier Ltd. All rights reserved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
Over the past decade we have observed rapid development
in the specialty of facial vascularized composite allotrans-
plantation (VCA) with promising functional, aesthetic and
psychological outcomes. 1 At least 39 facial transplantations
(including Finland’s ﬁrst two cases) have so far been per-
formed in several centres worldwide. 2–21 Successful facial
VCA demands an effective and coherent multidisciplinary
program to be in place. 22–24 This program should address at
the outset the necessary ethical, legal and ﬁnancial obliga-
tions as well as include a well-prepared research protocol,
experts from multiple specialties and ultimately, careful pa-
tient selection. 
The process in establishing the Helsinki VCA program be-
gan ﬁve years ago and culminated in the ﬁrst two selected
patients successfully undergoing facial allotransplantation
in February 2016 and March 2018. We recently reported on
the surgical technique and one-year clinical outcome of our
ﬁrst case. 25 The current paper describes our experience in
the setting up of the Helsinki VCA program, details of the
protocol and a short description of our ﬁrst two cases. 
Methods and patients 
Permission 
Legal, hospital, ﬁnancial, and ethical requirements 
The Helsinki Facial VCA program was started in 2011 in the
Department of Plastic Surgery, Helsinki University Hospital
(HUH). In 2012, vascularized composite allografts were clas-
siﬁed as ‘organ’ transplants in Finland. This facilitated legal
permission to be granted by the Ministry of Health as well
as the National Supervisory Authority for Social Welfare and
Health (Valvira) and the Finnish Medicines Agency (Fimea). 
The HUH stipulated a requirement for the VCA program
to be aligned with the solid organ transplantation (SOT)
team. The main issue was to plan the multiorgan recovery
in tandem with the facial allograft recovery in order to en-
sure the safety of the vital organ recovery. The hospital also
required the VCA program to collaborate closely with the
Finnish national organ recovery organization. The hospitalgranted permission only after approval from the other SOT
teams. 
Ethical issues were given special consideration due to
the anticipated public interest and potentially controver-
sial nature of the program. HUH stipulated the requirement
for a medical ethicist to assess the ethical implications of
the program. Ethical analysis was divided into general is-
sues (evidence in support of this purely experimental treat-
ment, serious risks versus beneﬁts of non-life-saving treat-
ment, autonomy and requirements for truly informed de-
cision making, general issues related to organ transplants)
and issues speciﬁc for facial transplantation (differences to
other, non-visible organ transplants; aesthetic versus med-
ical goals; and most importantly, the potential social re-
actions to the program and the recipient’s perception of
these). 
The ﬁnal approval was based on the premise that the
program constituted “experimental care”. This enabled the
program to be ﬁnanced by the national health care system.
The VCA program was subjected to ﬁnancial evaluation by
the health municipality before granting permission to pro-
ceed. The cost for the ﬁrst post-transplant year was esti-
mated to be 150,000 €. Once approval was obtained, the
HUH gave the ﬁnal special authorization, and the ﬁrst pa-
tient was placed on the waiting list for facial VCA. 
The Helsinki VCA program was also intended to facilitate
the future possibility of other VCA’s such as hand, laryngeal
or abdominal wall transplantations. 
Team setup 
Multidisciplinary team setup ( Figure 1 ) 
The Helsinki University Hospital is a tertiary-care academic
university hospital with referral area of 1.9 million inhabi-
tants covering one third of the Finnish population. A team
of Plastic, maxillofacial and ENT surgeons specializing in
head and neck surgery, including 9 surgeons skilled in micro-
surgery, comprise the Helsinki facial VCA team. Collabora-
tion with the SOT team is of key importance and full access
is granted to the multiple subspecialties involved in solid
organ transplantation (immunology, infectious diseases,
psychiatry, rejection and skin pathology, internal medicine
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Figure 1 The Helsinki facial VCA team. 
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Figure 2 Organ recovery and transplant algorithm. 
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cnd the organ procurement organisation). In addition, the 
arious disciplines (anesthesiology, radiology, dentistry, oral 
hysiotherapy, physiotherapy, speech therapy, nutritional 
herapy and social services) constituting the Helsinki Head 
nd Neck Cancer Center Service dovetail perfectly with the 
eeds of the VCA program. The team includes dedicated op-
rating room nurses who prepare detailed operation check- 
ists for both the donor and recipient procedures. 
rgan transplantation in Finland 
y birth, each person in Finland is a presumed organ donor.
n 2016, there were 132 deceased organ donors in Finland 
24.7 per million population – the highest number in the 
ordic countries), 40% were over 60 years old, and currently
nly brain-dead donors are permitted. There is only one 
ransplant centre in Finland in which 399 solid organ trans-
lants were performed (61 transplantations per million of 
opulation) in 2016. Donor facial recovery is restricted to 
he Helsinki region in order to minimize the logistic chal- 
enges in spite of the reduction in the donor pool. 
onor consent and organ recovery organization 
 donor consent process and a specialised consent form for
acial transplantation was formulated with the SOT team. 
onsent for facial tissue donation was to be approached only 
nce consent for solid organ donation had been agreed. Fur-
hermore, only haemodynamically stable brain dead organ 
onors without a signiﬁcant need for vasoactive inotropic 
edication, with an accurate cephalometric match, appro- 
riate gender and ethnicity, age > 18 years and with blood
roup compatibility were to be considered. 
The coordination of the organ recovery operation was 
f critical importance ( Figure 2 ). This involved consider-
ble prior planning with the SOT surgeons and simultaneous 
perating was one of their key demands. Immediate inter- 
al core cooling of the donor organs at the time of circu-
atory arrest is the single most important aspect of any or-
an preservation technique. This is best achieved by the in 
itu infusion of a preservation solution chilled to 4 °C, at
he time of the circulatory arrest. 26 In a multiorgan recov-
ry, once all internal organs and the face are ready for re-
oval, cardioplegic and preservation ﬂuids are infused and 
he donor rapidly cooled. For the face, cold University ofisconsin solution is infused and this is followed by recov-
ry of the heart and lungs. Recovery of the facial tissues and
bdominal organs is then performed. 
The recipient patient’s debridement commences simul- 
aneously with the donor facial dissection and deﬁnitive de-
ridement at the time of donor perfusion. 
onor mask 
he provision of a donor mask was a mandatory require-
ent stipulated by the HUH; this in spite of open casket
urials being quite rare in Finland. A novel additive manu-
acturing (formerly three-dimensional 3D printing) process 
as developed and it’s various phases tested for the pro-
uction of a donor face mask that fulﬁlls the requirements
or facial restoration after facial recovery. 27 Data obtained 
rom the processing of a standardized digital image of the
onor’s face is used for the 3D modeling and printing of a
onor face mask. 
adaveric rehearsals 
ultiple simulated donor face dissections should be re- 
earsed. We performed these in the Helsinki University De-
artment of Forensic Medicine, Tampere Surgical Education 
entre in the Tampere University Hospital and Guy’s Campus
natomy Department at King’s College London, UK. 
ransplantation immunology 
LA-typing. The recipient patient is HLA-A, -B and -DR
yped. The donor patient is more widely HLA-typed with a
eal-Time PCR instrument (Roche Molecular Systems Inc., 
A, USA) and Linkage Biosciences HLA-ABCDRDQA1DQB1DP 
84 Typing Kit (Linkage Biosciences, CA, USA). 
LA antibodies. The recipient patient’s HLA antibodies are 
etermined using Luminex with OneLambda LABScreen®
ixed Class 1 & 2 and Single Antigen Class I and II kits
OneLambda). A mean ﬂuorecence level (MFI) of 1000 is 
sed as the cut off for a positive ﬁnding in single antigen
nalyses. 
rossmatching . Prior to ﬁnal transplantation a crossmatch 
etween donor blood T- and B-cells is performed using the
omplement dependent cytotoxicity method. A negative 
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Table 1 Immunological protocol. 
Induction therapy Maintenance therapy 
Pre-op on ward 
Mycophenolate mofetil) 1 g, p.o. 
Tacrolimus 0.1 mg /kg, p.o. 
Tacrolimus: 
- Trough levels 0–1 month (13–16 ng/ml), 2–6 months 
(10–15 ng/ml), > 6 months (6–8 ng/ml) 
In theatre 
Methylprednisolone 500 mg, i.v. 
Antithymocyte globulin, ATG 1,5 mg/kg, i.v. (infusion over 
2–3 hours) and for 5 days 
Mycophenolate mofetil 1 g x 2 p.o. 
Methylprednisolone tapering dose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 crossmatch is a requirement for proceeding with the face
transplant. In addition, a virtual crossmatch is performed. 
Immunosuppression protocol 
The immunosuppression regimen to attempt to prevent re-
jection includes thymoglobulin as induction therapy and
tacrolimus, mycophenolate mofetil, and corticosteroids as
maintenance therapy ( Table 1 ). 
Rejection diagnostics set-up 
For rejection monitoring, punch biopsies (4 mm in diameter)
are taken at recommended intervals and assess rejection
according to Banff consensus criteria 28,29 During the ﬁrst
month biopsies are taken at weekly intervals from the facial
graft and sentinel ﬂap. This is followed by monthly biopsies
(up to one year) and at 3-monthly intervals thereafter. The
biopsies are formalin-ﬁxed and routine hematoxylin–eosin
staining performed. At least four sections are performed
routinely. For possible further use, slides for immunostain-
ings are also prepared. A sentinel ﬂap has been shown to
be a useful tool for rejection monitoring in facial transplan-
tation as it provides a clinical and histological indicator of
rejection. It can also be useful in distinguishing a facial der-
matitis from a clinical picture of rejection. 30 
Antimicrobial approach 
The patient undergoes serological screening for relevant in-
fectious diseases (Hepatitis A, B, C, E, Cytomegalovirus,
Varicella zoster, Epstein-Barr virus, Human herpes virus 6,
Human immunodeﬁciency virus, Syphilis, Tuberculosis, Tox-
oplasma) and appropriate vaccines are administered (Pneu-
mococci, Meningococci, Haemophilus inﬂuenzae type B,
hepatitis A,B, Diphtheria, Tetanus, seasonal inﬂuenza and
chicken pox if the patient is not naturally immunized). 
In Epstein-Barr virus (EBV) negative recipients EBV
positive donors are contraindicated. With regard to cy-
tomegalovirus (CMV) prophylaxis, the patient receives acy-
clovir for 3 months (recipient (R) negative / donor (D) nega-
tive), valganciclovir for 6 months (R + /D + or R + /D-), and
valganciclovir for 12 months (R-/D + ). Co-trimoxazole is
given for at least 6 months as a prophylactic regimen against
Toxoplasma gondii and Pneumocystis jirovecii . Periopera-
tively, antibiotic regimens are adjusted according to the re-
sults of cultures from both the donor and recipient. Antifun-
gal prophylaxis using anidulafungin is given after transplan-
tation for one week. 
Psychiatric evaluation protocol 
A preoperative evaluation aims to ensure that a candidate
has sufﬁcient psychological and social resources to copewith the transplantation process and be compliant with
lifelong immunosuppressive medication, rehabilitation, and
follow up. 31–33 The patient’s ability to receive and process
information is assessed in order to evaluate capability to
give informed consent. 34 A semi-structured interview by a
clinical psychologist takes place on at least 3 occasions and
aims to evaluate the candidate’s readiness and prepared-
ness for the operation and to predict psychological reac-
tions, possible risk factors and compliance with treatment
after transplantation. The extent to which cognitive tests
are used varies as some of the candidates may have pre-
existing brain damage or organic brain illness. 
A plan must also be in place for those candidates that
are deemed not to be a suitable transplantation candidate,
since these patients also need support and follow up. 
Finally, the VCA team must plan the postoperative
follow-up and support schedule. During the early postop-
erative period, assessment by a psychiatrist or psychologist
should be available once a week and following hospital dis-
charge every 1–2 months. In addition, every 6 months BDI
(Beck Depression Inventory), OASIS (Overall Anxiety Sever-
ity and Impairment Scale), and AUDIT (Alcohol Use Disorders
Identiﬁcation Test) questionnaires should be completed. 
Indications for facial transplantation 
We deﬁne the indications to include a functional facial de-
ﬁciency that cannot be reconstructed with conventional
techniques including functional loss of the oral and/or peri-
ocular sphincters and/or signiﬁcant loss of facial structures
in general. Absolute contraindications would include pre-
dicted non-compliance, recent history ( < 5 years) of malig-
nancy, psychiatric liability or severe chronic disease. How-
ever, the patient’s perspective is of fundamental impor-
tance with evidence of a signiﬁcantly poor quality of life
a chief determinant of suitability for facial VCA. 
Informed patient consent 
We ensure that the patients will be fully informed about
all the risks, post-operative course and possible sequelae.
Ultimately, it is the patient’s decision. 
Patients 
The population of Finland is 5.5 million and there are ﬁve
university hospitals that treat the most severe facial trauma
patients. Between 2011 and 2017 the Helsinki facial VCA
team has evaluated six patients. These patients have severe
facial aesthetic and functional deformities resulting from
Helsinki Face Transplant 177 
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aallistic injuries ( n = 3), burns ( n = 2) and neuroﬁbromato-
is ( n = 1). 
Functional assessment involved the analysis of: facial 
natomical region affected, loss of facial function (breath- 
ng, mastication, swallowing, speaking, labial competence 
nd eyelid closure), aesthetic defect, motor and sensory 
unction. Motor function was assessed using the Sunnybrook 
acial Grading System. Sensory function was assessed us- 
ng the Semmes Weinstein monoﬁlament test for light touch 
nd two-point discrimination. Quality of life (QOL) was as- 
essed using the generic 15D health related QOL instrument 
nd the European Organization for Research and Treatment 
f Cancer QOL Questionnaire (EORTC QLQ-Head & Neck 35 
odule). 
Two patients with severe soft tissue and bony midface 
eformities following earlier ballistic trauma were selected 
or facial transplantation. 
Patient 1 was a 35-year old blind male with a severe cen-
ral facial deformity involving maxilla and mandible and in- 
luding loss of facial height. He had severe symptoms re-
ated to nasal breathing, eating, speech, and recurrent soft 
issue infections. 
Patient 2 was a 59-year old male with a severe full facial
eformity also with involvement of maxilla and mandible. 
e had a permanent tracheostomy and problems with lip 
ompetence, eating, speech, and left eye dryness due to 
nsufﬁcient lid closure. 
There are two further patients in Finland currently un- 
er consideration for facial VCA, one patient following burn 
njury and the other following ballistic trauma. 
esults 
atient 1 
urgical procedure 
atient 1 was on the waiting list for two months prior to
ransplantation. He underwent successful face transplanta- 
ion in February 2016. The facial transplant consisted of a 
e Fort II maxilla, central mandible, lower ⅔ of the mid-
ace muscles, facial and neck skin, oral mucosa, anterior 
ongue and ﬂoor of mouth muscles, facial nerve (3 bilateral
ranches), and bilateral hypoglossal and buccal nerves. A 
entinel ﬂap (radial forearm ﬂap) recovered from the donor 
as used to provide skin biopsies for monitoring of rejec-
ion. 
Donor facial allograft retrieval duration was 6 hours (to- 
al multiorgan recovery duration was 10 hours), the duration 
f the recipient debridement was 10 hours and ﬁnal facial 
estoration 9 hours. The facial recovery was performed si- 
ultaneously with the SOT recovery according to the agreed 
lgorithm with no signiﬁcant deviations ( Figure 2 ). 
mmunological and medical outcome 
re-transplantation results. The donor had 4 mismatch- 
ng HLA-antigens (A ∗03, B ∗07, DRB1 ∗13, DRB1 ∗15). Cyto-
oxic crossmatches between the donor and recipient were egative for both T- and B-cells. The patient had preoper-
tively developed antibodies against B7 HLA antigen (MFI 
967), thus virtual crossmatch was positive. This ﬁnding was 
onsidered an increased immunological risk but not an ab-
olute contraindication. 
ost-transplantation results. At 30 months follow-up there 
ave thus far been no episodes of acute rejection and all
iopsies taken from the facial allograft and sentinel ﬂap
ave been Banff grade 0. Because of a fear of acute and
otential chronic rejection we elected against the ‘minimi- 
ation’ of immunosuppression. 
The patient developed a nasopalatinal ﬁstula on the 
eventh postoperative day and required three surgical at- 
empts until closure at 14 months. Plasma creatinine in-
reased two months after the operation and has decreased
o 1.2 mg/dl at 24 months. The patient suffered transient di-
betes during the initial period due to high doses of methyl-
rednisolone (up to 3 months postoperatively). The devel- 
pment of hypertension has also required medical ther- 
py. 
nfection results. The donor was CMV and toxoplasma neg-
tive but EBV positive. The recipient was both CMV and EBV
ositive, and toxoplasma negative. CMV-PCR has been nega- 
ive during the whole follow-up but EBV-PCR has been twice
lightly over the detection level. The patient has not had
ny other major bacterial or fungal infections. 
0-month functional outcome 
he patient has undergone intense physio-, occupational-, 
nd speech therapy. Follow up has also included regular
ental and ENT assessments. Functional assessments in- 
luded sensory evaluation (light touch, pain, 2 point dis-
rimination) at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24 and 30 months.
otor assessment involved manual muscle testing of fa- 
ial expression at similar time intervals and also included
he use of the Sunnybrook Facial Grading System and Elec-
romyography at 6, 12 and 24 months. 
At 30 months, the patient has a good aesthetic outcome
ith symmetrical restoration of the mobile central part of
he face with recovery of pain and light touch sensation to
he entire facial skin and intraoral mucosa and with sym-
etrical muscle activity in the ﬂoor of the mouth and facial
usculature and the patient is able to produce spontaneous 
mile. 
sychological results 
rior to transplantation, the patient exhibited a good and
table mental state with no psychiatric, psychological, or 
ubstance abuse problems diagnosed. Following transplan- 
ation regular contact with either the psychiatrist or psy-
hologist has been provided but no medication has been
eeded and his mental state has remained stable. At 24
onths postoperatively, the patient completed four ques- 
ionnaires: BDI, OASIS, Audit, and 15D. The results did not
uggest a risk of depression, anxiety or alcohol abuse. Suc-
essful social and psychological outcomes have also been 
bserved with improvement in some QOL domains (15D, 
ORTC H&N-35). These QOL questionnaires were completed 
t 6, 12 and 24 months post-operatively. 
178 A.J. Lindford et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Patient 2 
Surgical procedure 
Patient 2 awaited a donor for 15 months until success-
ful transplantation in March 2018. The transplant included
full-face soft tissues, Le Fort II maxilla, central mandible,
oral mucosa, ﬂoor of mouth muscles, bilaterally 4 branches
of the facial and hypoglossal nerves and bilateral sensory
nerves (supraorbital, infraorbital, buccal and mental). A
sentinel ﬂap (radial forearm ﬂap) was again recovered from
the donor to provide skin biopsies for monitoring of rejec-
tion. 
Donor facial allograft recovery duration was 6 hours (to-
tal multiorgan recovery duration was 11 h), the duration of
the recipient debridement was 12 h and ﬁnal facial restora-
tion 14 h. The facial recovery was again performed simul-
taneously with the SOT recovery according to the agreed
algorithm with no signiﬁcant deviations ( Figure 2 ). 
Immunological and early medical outcome 
Post-transplantation results 
Cytotoxic crossmatches between the donor and recipient
were negative for both T- and B-cells. The patient did not
present any preformed donor speciﬁc antibodies in the vir-
tual cross match. 
The patient spent 10 days on ICU and 6 weeks on the
ward. Of the postoperative problems, the patient developed
a unilateral parotid sialocele, and a partial necrosis of the
hard palate soft tissues and a small oronasal ﬁstula. The
sialocele was treated successfully with botulinum toxin and
the palatinal necrosis was revised and ﬁstula closed surgi-
cally. There has not been any medical complication or im-
munosuppressive medication related side effects so far. At
5 months, he has developed partial facial graft sensation
and slight movements of the transplanted orbicularis oris,
zygomatic and orbicularis oculi muscles. 
Financial cost 
The ﬁnancial cost of the operation was approximately
75,000 euros for patient 1 and the overall cost for the
ﬁrst year after transplantation was approximately 190,000
euros. 
Discussion 
The 5-year process in the setting-up of the Helsinki VCA pro-
gram required thorough planning and painstaking attention
to detail and resulted in successful face transplantation in
two patients in 2016 and 2018. At the earliest stage, an open
social dialogue was conducted consisting of an open seminar
for professionals and the press, prior to the start of the pro-
gram. This included analysis of the ethical issues to help
inform public debate. The planning phase received large
and overwhelmingly positive Finnish media coverage. Sub-
sequently, the legal, hospital, and ﬁnancial requirements
were each addressed before ﬁnal permission to proceed was
granted by the hospital authorities. The formation of the multidisciplinary team then be-
gan in earnest led by the Head of the HUH Head & Neck
Plastic surgery team (PL). A clinical protocol was com-
piled and drawing on the appropriate sub disciplines of the
Helsinki Head & Neck Cancer Centre and Helsinki SOT ser-
vice, a wide-ranging and well-equipped Multidisciplinary Fa-
cial VCA team was assembled. In particular, the immunolog-
ical and infection control aspects demanded careful anal-
ysis and planning. This was in view of the fact that these
elements have to date been implicated in nearly all cases
of facial VCA transplant patient morbidity and or mortal-
ity and constitutes the major overall risk of the procedure.
In addition, the post-operative rehabilitation protocol war-
ranted clear and focused multidisciplinary planning to meet
the multiple challenges likely to be encountered during the
recovery period. 
The indications for facial VCA were clearly deﬁned as
those central facial anatomical defects unable to be sat-
isfactorily reconstructed by conventional means. However,
the focus would be the patient and a clear potential beneﬁt
to his/her quality of life was essential for inclusion into the
VCA program. The psychological assessment was of funda-
mental importance in ensuring that a selected patient had
the required resources to cope with the magnitude of the
operation and life-long immunosuppression. Furthermore,
our two selected patients are both victims of self-inﬂicted
ballistic trauma and hence effective psychiatric screening
and conﬁrmation of a strong social network are pertinent.
Indeed, both patients have remained psychologically sta-
ble throughout the peri-operative and post-operative period
with improvement in several quality of life domains in the
ﬁrst patient. Of note, our ﬁrst patient has complete bilat-
eral blindness but a previous position paper had concluded
that blind patients could be included in facial VCA programs
on the basis of functional, social, rehabilitative and ethical
grounds. 35 
During the ﬁve-year developmental process and estab-
lishment of the Helsinki Facial VCA programme considerable
planning was involved concerning the logistics and coordi-
nation of the face transplant operation. The importance of
a team approach cannot be overstated. In particular the
synchronous procurement protocol needs to be carefully
planned with the SOT surgeons. 36–40 In our institution the
facial procurement occurs in a physically separate hospi-
tal site to the recipient operation. This presented its own
challenges with the continuous and effective, dynamic com-
munication between both the procurement and recipient
teams essential for success. Furthermore, the duration of
the recipient debridement operation was longer than the
donor face harvest. This was anticipated yet still presented
a difﬁculty in planning the synchronization of both opera-
tions. The recipient debridement cannot be commenced too
early in case the donor allograft fails or problems are en-
countered during the multiorgan recovery operation. Con-
versely, if the donor facial allograft is detached too soon,
the problem of increasing ischaemia time would be encoun-
tered. Thus, we had to deﬁne the point of no return and ini-
tiate deﬁnitive debridement at a stage when the transplant
feasibility was certain ( Figure 2 ). Thus, cadaver practicing
was essential for the planning of the harvesting algorithm
as well as for the timing of the donor mask manufactur-
ing. 
Helsinki Face Transplant 179 
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1  Our ﬁrst two patients underwent successful facial trans- 
lantation and their data have been submitted to the Inter-
ational Registry for Hand and Composite Tissue Allotrans- 
lantation (IRHCTT). With regards to patient 1, although the 
atient has encountered various postoperative challenges 
ncluding infectious episodes, immunosuppression related 
ide-effects and a need for surgical corrections; all of these 
hallenges have been successfully managed by the multidis- 
iplinary team. 25 
Pertinently, we have not observed any clinical nor his- 
ological signs of acute rejection (at 30 months follow-up). 
his is in spite of the presence of a 4/6 HLA mismatch and
nitial donor speciﬁc Class-I HLA antibody at the time of
ransplantation. The absence of rejection may in part be 
ccounted for by appropriate patient selection and compli- 
nce as well as close continuous physician contact during 
he rehabilitation period. Non-compliance is a major risk 
actor for acute rejection and graft failure of renal trans-
lants. 41,42 Hence, the patient is likely to beneﬁt from close, 
egular, and long-term contact in order to preserve moti- 
ation for compliance as well as for successful functional 
acial outcome. More importantly, various aspects of speak- 
ng, swallowing and breathing should be covered by the re-
abilitation phase in the programme. Therefore, the team 
hould include a holistic plan for long-term follow-up with 
imilar intensity and emphasis on psychosocial factors. 
The actual cost for the transplantation exceeded the es- 
imated budget by 25%. Most of the extra costs were related
o additional unplanned but necessary corrective surgical 
rocedures. All the VCA program costs in Finland are cov- 
red by the state, since the program belongs to the National
rgan Transplant program. This is in contrast with many 
ther countries where active centers or programs at an early
et-up phase are suffering from ﬁnancial difﬁculties due to 
eliance on non-state sponsors. 43 Therefore, secure state 
ponsorship is beneﬁcial for a long-term survival of a VCA
rogram. Furthermore, there is a need for more objective 
easurements of pre- and post-transplant results. Current 
ata in the literature are somewhat lacking in describing the
rue value that face transplantation provides. Current QOL 
easures are not effective in measuring the improvements 
peciﬁc to the function of the face. The Cleveland Clinic has
reviously proposed the FACES Score 44 , and more recently 
he Face-Q (a patient reported outcome tool for head and 
eck reconstruction) has also been described. 45 The latter 
ould potentially be adapted for the face transplant popu- 
ation. 
The issue of population size in relation to the provision 
f a facial VCA program needs further consideration. Our 
econd patient had been on the waiting list for 15 months in
pite of three suitable donors. Whilst consent was obtained 
or solid organ procurement the next of kin declined the
onation of the facial tissues. This underlines the need for
 large donor catchment area especially for preimmunized 
atients for whom suitable donors are more scarce. In addi-
ion, a requirement for an active facial VCA center should 
e an adequate number of selected patients for transplan- 
ation. Thus, Finland with its small population size, raises 
he question for the future regarding possible centraliza- 
ion of our VCA program to serve the Northern European
egion. One argument to support this view is the fact that
ll the ﬁve Nordic countries share a rather similar public ealth-care system, which is regulated by governmental au- 
horities. 
In conclusion, we described the long and thorough pro-
ess involving numerous medical disciplines in establishing 
he Helsinki Facial VCA protocol and resulting in the ﬁrst two
uccessful Northern European facial transplantation cases in 
016 and 2018. 
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